DE3839639A1 - USE OF TNF IN THE TREATMENT OF SKIN DISEASES - Google Patents

USE OF TNF IN THE TREATMENT OF SKIN DISEASES

Info

Publication number
DE3839639A1
DE3839639A1 DE3839639A DE3839639A DE3839639A1 DE 3839639 A1 DE3839639 A1 DE 3839639A1 DE 3839639 A DE3839639 A DE 3839639A DE 3839639 A DE3839639 A DE 3839639A DE 3839639 A1 DE3839639 A1 DE 3839639A1
Authority
DE
Germany
Prior art keywords
tnf
treatment
skin diseases
inflammatory skin
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE3839639A
Other languages
German (de)
Inventor
Achim Dr Moeller
Alexander Dr Kapp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to DE3839639A priority Critical patent/DE3839639A1/en
Priority to EP89913085A priority patent/EP0445178A1/en
Priority to PCT/EP1989/001412 priority patent/WO1990005532A1/en
Priority to JP2500042A priority patent/JPH04501720A/en
Publication of DE3839639A1 publication Critical patent/DE3839639A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of TNF in the treatment of inflammatory skin diseases is described.

Description

TNF-α und TNF-β sind bereits seit längerer Zeit bekannt. Sie wirken cyto­ toxisch und zeigen ein breites Spektrum an Aktivitäten (Lymphokines 14, 203-223 (1987)).TNF- α and TNF- β have been known for a long time. They are cyto-toxic and show a broad spectrum of activities (Lymphokines 14, 203-223 (1987)).

Es wurde nun gefunden, daß sich TNF zur Behandlung von Hauterkrankungen eignet.It has now been found that TNF is used to treat skin disorders is suitable.

Gegenstand der Erfindung ist die Verwendung von TNF bei der Behandlung von entzündlichen Hauterkrankungen.The invention relates to the use of TNF in the treatment of inflammatory skin diseases.

Gegenstand der Erfindung sind weiter äußerlich applizierbare Arzneimittel­ zubereitungen, die TNF enthalten.The invention further relates to medicaments which can be applied externally preparations containing TNF.

Der Begriff "TNF" schließt TNF-α (= Tumornekrosefaktor) und TNF-β (= Lymphotoxin) sowie deren Muteine ein. Solche Muteine sind beispiels­ weise beschrieben in EP 1 64 965, EP 1 68 214, EP 2 05 038, EP 2 51 037, WO 86/02 381 und DE 36 20 656.The term "TNF" includes TNF- α (= tumor necrosis factor) and TNF- β (= lymphotoxin) and their muteins. Such muteins are described, for example, in EP 1 64 965, EP 1 68 214, EP 2 05 038, EP 2 51 037, WO 86/02 381 and DE 36 20 656.

Als entzündliche Hauterkrankung kommt insbesondere atopische Dermatitis in Betracht.Atopic dermatitis, in particular, is an inflammatory skin disease Consider.

Als äußerlich applizierbare Arzneimittelzubereitungen eignen sich Pulver, Lösungen, Lotionen, Salben, Cremes oder Sprays. Diese können mit den üblichen galenischen Hilfsmitteln wie Konservierungsmitteln, Lösungsmitteln und Treibgasen verarbeitet sein (vgl. H. Sucker et. al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart 1978). Die so erhaltenen Applikationsformen enthalten den Wirkstoff normalerweise in einer Menge von 10-5 bis 10-6 Gewichtsprozent. Die so erhaltenen Zubereitungen werden in der Regel 2-3mal täglich auf die entzündete Hautstelle aufgetragen.Powder, solutions, lotions, ointments, creams or sprays are suitable as externally applicable pharmaceutical preparations. These can be processed with the usual pharmaceutical auxiliaries such as preservatives, solvents and propellants (cf. H. Sucker et. Al .: Pharmaceutical Technology, Thieme-Verlag, Stuttgart 1978). The application forms thus obtained normally contain the active ingredient in an amount of 10 -5 to 10 -6 percent by weight. The preparations obtained in this way are usually applied to the inflamed area of skin 2-3 times a day.

Beispiel 1example 1

In üblicher Weise wird eine Salbe folgender Zusammensetzung hergestellt:An ointment of the following composition is produced in the usual way:

49,0 g Wasser enthaltend 1 mg TNF-α
3,0 g Wollwaschalkohol
0,25 g Cetylsterarylalkohol
47,55 g weiße Vaseline
0,2 g p-Hydroxybenzoesäurepropylester 49.0 g water containing 1 mg TNF- α
3.0 g of wool washing alcohol
0.25 g cetylsteraryl alcohol
47.55 g of white petroleum jelly
0.2 g propyl p-hydroxybenzoate

Beispiel 2Example 2

In üblicher Weise wird eine Creme folgender Zusammensetzung hergestellt:A cream of the following composition is produced in the usual way:

67,0 g Wasser enthaltend 1 mg TNF-β
8,0 g Cetylstearylalkohol
3,5 g polyethoxyliertes hydriertes Ricinusöl
15,3 g dickflüssiges Paraffin
6,0 g weiße Vaseline
0,2 g p-Hydroxybenzoesäurepropylester67.0 g water containing 1 mg TNF- β
8.0 g cetylstearyl alcohol
3.5 g polyethoxylated hydrogenated castor oil
15.3 g of viscous paraffin
6.0 g of white petroleum jelly
0.2 g propyl p-hydroxybenzoate

Claims (3)

1. Verwendung von TNF bei der Behandlung von entzündlichen Haut­ erkrankungen.1. Use of TNF in the treatment of inflammatory skin diseases. 2. Verwendung von TNF bei der Behandlung von atropischer Dermatitis.2. Use of TNF in the treatment of atropic dermatitis. 3. Äußerlich applizierbare Arzneimittelzubereitungen, die TNF enthalten.3. Topical pharmaceutical preparations that contain TNF.
DE3839639A 1988-11-24 1988-11-24 USE OF TNF IN THE TREATMENT OF SKIN DISEASES Withdrawn DE3839639A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE3839639A DE3839639A1 (en) 1988-11-24 1988-11-24 USE OF TNF IN THE TREATMENT OF SKIN DISEASES
EP89913085A EP0445178A1 (en) 1988-11-24 1989-11-21 Use of tnf in the treatment of skin diseases
PCT/EP1989/001412 WO1990005532A1 (en) 1988-11-24 1989-11-21 Use of tnf in the treatment of skin diseases
JP2500042A JPH04501720A (en) 1988-11-24 1989-11-21 Use of TNF in the treatment of skin diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3839639A DE3839639A1 (en) 1988-11-24 1988-11-24 USE OF TNF IN THE TREATMENT OF SKIN DISEASES

Publications (1)

Publication Number Publication Date
DE3839639A1 true DE3839639A1 (en) 1990-05-31

Family

ID=6367784

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3839639A Withdrawn DE3839639A1 (en) 1988-11-24 1988-11-24 USE OF TNF IN THE TREATMENT OF SKIN DISEASES

Country Status (4)

Country Link
EP (1) EP0445178A1 (en)
JP (1) JPH04501720A (en)
DE (1) DE3839639A1 (en)
WO (1) WO1990005532A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190750A (en) * 1990-03-09 1993-03-02 Asahi Kasei Kogyo Kabushiki Kaisha Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189251B (en) * 1982-04-07 1986-06-30 Asahi Kasei Kogyo Kk,Jp Process for stabilizing tumor necrosis factor
DE3631413A1 (en) * 1986-09-16 1988-03-24 Knoll Ag THERAPEUTIC SYSTEM FOR LOCAL APPLICATION OF PHARMACEUTICAL ACTIVE SUBSTANCES
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials

Also Published As

Publication number Publication date
WO1990005532A1 (en) 1990-05-31
EP0445178A1 (en) 1991-09-11
JPH04501720A (en) 1992-03-26

Similar Documents

Publication Publication Date Title
DE3856018T2 (en) Use of a disaccharide polysulfate-aluminum compound for the manufacture of a medicament for the treatment of HÄMORRHOIDEN and for wound healing
DE69733086T2 (en) PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN KUUU NUTS OIL
DE69520041T2 (en) MEDICINAL PRODUCTS BASED ON A SYNERGISTIC MIXTURE OF METRONIDAZOLE AND CLINAMICIN
DE69731610T2 (en) ORAL ADMINISTRATION OF EFFECTIVE QUANTITIES OF HYALURONIC ACID
DE3413052A1 (en) PHARMACEUTICAL PREPARATION AND THE USE THEREOF FOR TREATING SKIN DISEASES
DE69027220T2 (en) COMPOSITION AND METHOD FOR TREATING PAINFUL INFLAMMABLE OR ALLERGIC DISEASES
DE19737348C2 (en) Pharmaceutical composition containing clindamycin and clotrimazole
DE69619052T2 (en) Solid, anhydrous, pharmaceutical preparations for vaginal use
EP0133151A2 (en) Skin ointment
WO1989006962A1 (en) Silver sulfadiazine-containing agent for topical external therapy
DE3011437A1 (en) PHARMACEUTICAL AGENT FOR HEALING INFLAMMABLE AND / OR DEGENERATIVE AND / OR ATROPHIC MUSCULAR DISEASES
DE69730214T2 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF HERPES SIMPLEX
DE69303305T2 (en) Means of treating chronic fatigue
DE3443242A1 (en) Glycyrrhizin and a medicament containing an active compound
DE60206270T2 (en) COMPOSITIONS CONTAIN THYLAKOIDS FOR MODULATING INFLAMMATION
DE3839639A1 (en) USE OF TNF IN THE TREATMENT OF SKIN DISEASES
DE69424679T2 (en) COMPOSITION FOR TREATING OR PREVENTING HERPES
EP0697878B1 (en) New use of equisetum
DE2720420A1 (en) COMBINATION OF ACTIVE INGREDIENTS AGAINST SUNNYTHEM AND MEDICINAL PRODUCT CONTAINING THIS
DE3830333C1 (en) Pharmaceutical composition for the treatment of the eruption caused by herpes viruses
WO1996033707A1 (en) Topical preparation for promoting muscular development
DE68905788T2 (en) LOCAL MEDICINAL PRODUCTS CONTAINING TICLOPIDINE.
DE3633651C2 (en)
DE69716769T2 (en) PREPARATIONS FOR THE TREATMENT OF BURNS AND EXTERNAL ULCERA AND METHOD FOR THE PRODUCTION THEREOF
CH677878A5 (en)

Legal Events

Date Code Title Description
8130 Withdrawal